Celsion to Present Two Posters on its GEN-1 IL-12 Gene-Mediated Immunotherapy at the ASCO-SITC Clinical Immuno-Oncology Sympo...
January 19 2017 - 8:00AM
Celsion Corporation (NASDAQ:CLSN) today announced that it will
present two posters at the American Society of Clinical Oncology
(ASCO) - Society for Immunotherapy of Cancer (SITC) Clinical
Immuno-Oncology Symposium being held from February 23 – 25, 2017 in
Orlando, FL. The symposium will focus on the latest clinical
and translational research in immuno-oncology and the implications
for clinical care. The first poster will report clinical
results from the Phase Ib dose escalating clinical trial (the
OVATION Study) combining GEN-1, the Company's IL-12 gene-mediated
immunotherapy, with the standard of care for the treatment of
newly-diagnosed patients with Stage III and IV ovarian cancer who
will undergo neoadjuvant chemotherapy followed by interval
debulking surgery. The second poster will report
translational data from the OVATION Study and previous GEN-1
clinical trials. The posters will be presented by Khursheed
Anwer, Ph.D., Celsion’s executive vice president and chief science
officer.
Poster Presentation
details:
Title: Phase I study and
activity of formulated IL-12 plasmid administered intraperitoneally
in combination with standard neoadjuvant chemotherapy in patients
with newly diagnosed advanced stage ovarian cancer
Date and Time: Poster Session A
– February 23, 2017 (11:30 am – 1:00 pm ET; 5:30 pm to 6:30 pm
ET)
Poster Number: 155
Title: Immunological changes
following intraperitoneal administration of a formulated IL-12
plasmid in combination with standard neoadjuvant chemotherapy in
patients with newly diagnosed advanced stage ovarian cancer
Date and Time: Poster Session A
– February 23, 2017 (11:30 am – 1:00 pm ET; 5:30 pm to 6:30 pm
ET)
Poster Number: 156
“Our hypothesis is that GEN-1 plus neoadjuvant
chemotherapy treatment will reprogram the tumor immune
microenvironment towards a potent antitumor immune response,” said
Dr. Anwer. “The available data demonstrate highly relevant
immunological changes in the tumor immune environment, such as
tumor infiltration of cytotoxic T-cell lymphocytes and a reduction
of certain immunosuppressive signals, which supports the immune
activating role of GEN-1 in this patient population. Evidence
of immune activation following the treatment is also supported by
increases in IFN-g, a potent mediator of the anti-tumor immune
response associated with IL-12 action. We are excited to
present at the ASCO-SITC symposium, and look forward to sharing the
impressive clinical and translational results with the scientific
community.”
The OVATION Study is designed to enroll three to
six patients per dose cohort with the goal of identifying a safe,
tolerable and immunologically active dose of GEN-1 by recruiting
and maximizing an immune response. Enrollment in the fourth cohort
is ongoing with the goal of enrolling three additional patients in
this final dose cohort. Celsion expects to complete
enrollment in the OVATION Study this quarter and report final data,
including translational data for all patients, in the second
quarter of 2017. Future studies of GEN-1 will include a Phase I/II
study combining GEN-1 with Avastin® and Doxil®.
About Celsion
Corporation
Celsion is a fully-integrated oncology company
focused on developing a portfolio of innovative cancer treatments,
including directed chemotherapies, immunotherapies and RNA- or
DNA-based therapies. The Company's lead program is ThermoDox®, a
proprietary heat-activated liposomal encapsulation of doxorubicin,
currently in Phase III development for the treatment of primary
liver cancer and in Phase II development for the treatment of
recurrent chest wall breast cancer. The pipeline also includes
GEN-1, a gene-mediated immunotherapy for the localized treatment of
ovarian and brain cancers. Celsion has two platform technologies
for the development of novel nucleic acid-based immunotherapies and
other anticancer DNA or RNA therapies, including TheraPlas™ and
TheraSilence™. For more information on Celsion, visit our website:
http://www.celsion.com. (CLSN-G1 CLSN-OV)
Celsion wishes to inform readers that
forward-looking statements in this release are made pursuant to the
"safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Readers are cautioned that such
forward-looking statements involve risks and uncertainties
including, without limitation, unforeseen changes in the course of
research and development activities and in clinical trials; the
uncertainties of and difficulties in analyzing interim clinical
data, particularly in small subgroups that are not statistically
significant; FDA and regulatory uncertainties and risks; the
significant expense, time, and risk of failure of conducting
clinical trials; the need for Celsion to evaluate its future
development plans; possible acquisitions or licenses of other
technologies, assets or businesses; possible actions by customers,
suppliers, competitors, regulatory authorities; and other risks
detailed from time to time in the Celsion's periodic reports and
prospectuses filed with the Securities and Exchange
Commission. Celsion assumes no obligation to update or
supplement forward-looking statements that become untrue because of
subsequent events, new information or otherwise.
Celsion Investor Contact
Jeffrey W. Church
Sr. Vice President and CFO
609-482-2455
jchurch@celsion.com
Celsion (NASDAQ:CLSN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Celsion (NASDAQ:CLSN)
Historical Stock Chart
From Sep 2023 to Sep 2024